Myriad Genetics, Inc. (MYGN)
| Market Cap | 380.69M -43.5% |
| Revenue (ttm) | 806.60M -3.2% |
| Net Income | -112.60M |
| EPS | -1.20 |
| Shares Out | 95.65M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 82,835 |
| Open | 3.750 |
| Previous Close | 3.880 |
| Day's Range | 3.750 - 3.850 |
| 52-Week Range | 2.740 - 8.590 |
| Beta | 1.68 |
| Analysts | Hold |
| Price Target | 3.37 (-15.33%) |
| Earnings Date | Nov 2, 2026 |
About MYGN
Myriad Genetics, Inc., a molecular diagnostics and precision medicine company, develops molecular tests. The company offers molecular diagnostic tests for oncology, women’s health, and pharmacogenomics. It also provides MyRisk Hereditary Cancer test, a DNA sequencing test for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic test, a DNA sequencing test for metastatic breast, ovarian, metastatic pancreatic, and metastatic prostate cancer with deleterious or suspected deleterious germline BRCA variants; and MyChoice CDx Companion... [Read more]
Financial Performance
In 2025, Myriad Genetics's revenue was $824.50 million, a decrease of -1.56% compared to the previous year's $837.60 million. Losses were -$365.90 million, 187.4% more than in 2024.
Financial StatementsAnalyst Summary
According to 10 analysts, the average rating for MYGN stock is "Hold." The 12-month stock price target is $3.37, which is a decrease of -15.33% from the latest price.
News
Myriad Genetics Appoints Vishal Sikri Executive Vice President - Commercial
SALT LAKE CITY, Sept. 16, 2026 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. , (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, today announced that Vishal Sikri has been p...
Myriad Genetics Transcript: Wells Fargo 21st Annual Healthcare Conference
Q2 saw revenue and ASP declines due to prenatal and hereditary cancer reimbursement pressures, leading to conservative guidance. Strategic initiatives like Project Ascend and a portfolio review focus on cancer care, while new products and operational improvements aim to drive future growth.
Myriad Genetics assumed with a Neutral at UBS
UBS assumed coverage of Myriad Genetics (MYGN) with a Neutral rating and $3.60 price target The firm initiated and resumed 25 life science and diagnostics tools companies. UBS views life…
This Biotech Stock Got a Rare Double-Downgrade. Its Profitability Problem Just Got Worse.
Piper Sandler cuts Myriad Genetics stock to Underweight, citing doubts about the genetic testing company's path to sustainable profitability.
Myriad Genetics downgraded to Underweight from Overweight at Piper Sandler
Piper Sandler double downgraded Myriad Genetics (MYGN) to Underweight from Overweight with a price target of $2, down from $5.45. Piper does not believe Myriad’s current business model can grow…
Myriad Genetics to Present at 2026 Wells Fargo Healthcare Conference
SALT LAKE CITY, Aug. 27, 2026 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, today announces Myriad management will present ...
Myriad Genetics price target lowered to $3 from $5 at Stephens
Stephens lowered the firm’s price target on Myriad Genetics (MYGN) to $3 from $5 and keeps an Equal Weight rating on the shares. Myriad Genetics’ shares fell more than 40%…
MYGN Investors Have Opportunity to Join Myriad Genetics, Inc. Fraud Investigation with SBS Law
LOS ANGELES--(BUSINESS WIRE)---- $MYGN--MYGN Investors Have Opportunity to Join Myriad Genetics, Inc. Fraud Investigation with SBS Law.
Myriad Genetics, Inc. (MYGN) Investors Who Suffered Losses Are Encouraged to Contact Johnson Fistel
SAN DIEGO, Aug. 04, 2026 (GLOBE NEWSWIRE) -- Johnson Fistel, PLLP is investigating whether Myriad Genetics, Inc. (“Myriad Genetics” or the “Company”) (NASDAQ: MYGN) or certain of its officers and dire...
Myriad Genetics price target lowered to $3 from $5.50 at Wells Fargo
Wells Fargo lowered the firm’s price target on Myriad Genetics (MYGN) to $3 from $5.50 and keeps an Equal Weight rating on the shares. The firm notes shares were down…
Myriad Genetics price target lowered to $3.20 from $4 at BofA
BofA lowered the firm’s price target on Myriad Genetics (MYGN) to $3.20 from $4 and keeps an Underperform rating on the shares. The firm updated its estimates after the company’s…
Myriad Genetics price target lowered to $4 from $6 at TD Cowen
TD Cowen analyst Dan Brennan lowered the firm’s price target on Myriad Genetics (MYGN) to $4 from $6 and keeps a Hold rating on the shares. The firm said the…
Myriad Genetics cuts FY26 revenue view to $770M-$790M from $860M-$880M
Consensus $863.58M. Sees FY26 adjusted gross margin 66%-67%. The company said, “Revised the full-year 2026 revenue range lower, reflecting Q2 results and current business trends.”
Myriad Genetics reports Q2 EPS (25c), consensus (6c)
Reports Q2 revenue $190.7M, consensus $206.03M. “In the second quarter, we continued to make meaningful progress on the Cancer Care Continuum on a number of fronts, including 6% year-over-year volume…
Myriad Genetics Earnings Call Transcript: Q2 2026
Q2 2026 revenue fell 11% year-over-year to $190.7 million, driven by lower prenatal volumes and payer reimbursement friction, despite strong hereditary cancer and mental health test growth. Guidance for 2026 revenue and gross margin was lowered, and operational initiatives are underway to address reimbursement and efficiency challenges.
Myriad Genetics Earnings release: Q2 2026
Myriad Genetics released its Q2 2026 earnings on July 30, 2026, summarizing the period's financial results.
Myriad Genetics Slides: Q2 2026
Myriad Genetics has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on July 30, 2026.
Myriad Genetics Quarterly report: Q2 2026
Myriad Genetics has published its Q2 2026 quarterly earnings report on July 30, 2026.
Myriad Genetics Reports Second Quarter 2026 Financial Results; Deploying New Initiatives Focused on Driving Increased Efficiency, Productivity and Scalability
Highl ights Second quarter 2026 revenue of $190.7 million decreased 11% year-over-year, reflecting a 1% decline in volume and a 9% decrease in average revenue per test year-over-year. The company is e...
Myriad Genetics to Release Second Quarter 2026 Financial Results on July 30, 2026
SALT LAKE CITY, July 23, 2026 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, will hold its second quarter 2026 earnings con...
Myriad Genetics Launches FirstGene® Multiple Prenatal Screen
Myriad Genetics Launches FirstGene® Multiple Prenatal Screen: The only lab test to run four prenatal genetic screens simultaneously as early as eight weeks
New Large-Scale Meta-Analysis Demonstrates Strong Prognostic Performance of Myriad's Prolaris® Biopsy Test in Localized Prostate Cancer
New published data shows Prolaris Biopsy Test adds significant prognostic information beyond conventional clinical risk categories for prostate cancer.
Myriad Genetics Expands Availability of Precise MRD™ for Colorectal, Renal and Breast Cancers, Supported by New Publication
Publication of MONITOR-Breast study marks latest milestone for clinical validity of Precise MRD Publication of MONITOR-Breast study marks latest milestone for clinical validity of Precise MRD
Myriad Genetics Transcript: AGM 2026
The meeting covered director elections, auditor ratification, executive compensation, and equity plan approvals, with all proposals passing by majority vote. No stockholder questions were raised, and management highlighted risks associated with forward-looking statements.
Myriad Genetics appoints Raj Jampa as chief technology officer
Myriad Genetics (MYGN) announced the appointment of Raj Jampa as chief technology officer, effective June 1. As CTO, Jampa will be responsible for strategy and execution of Myriad’s technology organiz...